Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Open
Phase 3
This trial is comparing a new drug called MK-3475A with pembrolizumab for non small cell lung cancer (NSCLC).
It is for people:
who are having their first treatment for NSCLC that has spread to another part of the body
with a large number of cancer cells that have a called PD-L1
Recruitment start: 21 February 2025
Recruitment end: 15 January 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Toby Talbot
Merck Sharp & Dohme Ltd
Last reviewed: 1 July 2025
CRUK internal database number: 20010
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
